Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Hold Placed on UCB/Immunomedics Lupus Biologic

This article was originally published in The Pink Sheet Daily

Executive Summary

Immunomedics says manufacturing issue should not derail Phase III trial.

You may also be interested in...



FDA Lifts Clinical Hold On UCB/Immunomedics Epratuzumab Lupus Trial

Firms will submit protocol amendments to institutional review boards.

FDA Lifts Clinical Hold On UCB/Immunomedics Epratuzumab Lupus Trial

Firms will submit protocol amendments to institutional review boards.

May The Schwarz Be With You: UCB Proposes $5.6 Bil. Acquisition

Existing Schwarz deal with Pfizer unaffected by merger that would create a neurology heavyweight.

Topics

UsernamePublicRestriction

Register

PS064921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel